Compare KeyCorp (KEY) vs 10X Genomics Inc (TXG) Price & Performance

KeyCorp (KEY) trades at $23.26, down 1.23% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Strong fundamentals include a 26.05% net income margin and 10.61% ROE, while valuation metrics show a P/E of 14.45 and P/B of 1.45. Recent corporate actions include consistent quarterly dividends of $0.21 per share and a new $3 billion buyback program announced in July 2026.

KEY presents a compelling investment case with analyst consensus pointing to significant upside (price target $30.50, 31% potential). The combination of earnings momentum, shareholder-friendly capital returns, and improving loan growth supports bullish sentiment. However, risks include potential pressure on net interest margins from Fed policy and competitive challenges in regional banking. The stock's current valuation appears reasonable relative to earnings growth prospects.

TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.

The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.